Nanomaterial-based Drug Delivery Research Articles

From Biosensors to Robotics: Pioneering Advances in Breast Cancer Management.

Breast cancer stands as the most prevalent form of cancer amongst females, constituting more than one-third of all cancer cases affecting women. It causes aberrant cell development, which can assault or spread to other sections of the body, perhaps leading to the patient's death. Based on research findings, timely detection can diminish the likelihood of mortality and enhance the quality of healthcare provided for the illness. However, current technologies can only identify cancer at an advanced stage. Consequently, there is a substantial demand for rapid and productive approaches to detecting breast cancer. Researchers are actively pursuing precise and timely methods for the diagnosis of breast cancer, aiming to achieve enhanced accuracy and early detection. Biosensor technology can allow for the speedy and accurate diagnosis of cancer-related cells, as well as a more sensitive and specialized technique for generating them. Additionally, numerous treatments for breast cancer are depicted such as herbal therapy, nanomaterial-based drug delivery, miRNA targeting, CRISPR technology, immunotherapy, and precision medicine. Early detection and efficient therapy are necessary to manage such a severe illness properly.

Nano-Bio Interfaces: Pioneering Targeted Approaches for Disease Treatment and Prevention

Nanotechnology has emerged as a pivotal force in biomedical research, offering groundbreaking solutions for disease treatment and prevention through the integration of nanoscience with biology. This review explores the multifaceted applications of nano-bio interfaces in revolutionizing therapeutic interventions and public health strategies. At the forefront of innovation, nanomaterial-based drug delivery systems demonstrate unparalleled precision and efficacy in targeted drug delivery, minimizing systemic toxicity and maximizing therapeutic outcomes. Furthermore, the development of multifunctional nanoparticles capable of simultaneous drug delivery and diagnostic imaging enables real-time monitoring of treatment responses, heralding a new era of personalized medicine. Nano-bio interfaces also play a crucial role in advancing vaccine development and immunotherapies, with nanoparticle-based vaccine platforms offering enhanced antigen delivery and immune stimulation for robust and durable immune responses against infectious diseases and cancer. In the realm of disease prevention, antimicrobial nanomaterials provide effective strategies for infection control, while nanovaccines and prophylactic drug delivery systems offer tailored solutions for mitigating the spread of infectious agents. Through a comprehensive exploration of these pioneering approaches, this review, we believe, highlights the transformative potential of nano-bio interfaces in reshaping the landscape of disease treatment and prevention.

Research Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer.

Colorectal cancer (CRC) is a common type of gastrointestinal tract (GIT) cancer and poses an enormous threat to human health. Current strategies for metastatic colorectal cancer (mCRC) therapy primarily focus on chemotherapy, targeted therapy, immunotherapy, and radiotherapy; however, their adverse reactions and drug resistance limit their clinical application. Advances in nanotechnology have rendered lipid nanoparticles (LNPs) a promising nanomaterial-based drug delivery system for CRC therapy. LNPs can adapt to the biological characteristics of CRC by modifying their formulation, enabling the selective delivery of drugs to cancer tissues. They overcome the limitations of traditional therapies, such as poor water solubility, nonspecific biodistribution, and limited bioavailability. Herein, we review the composition and targeting strategies of LNPs for CRC therapy. Subsequently, the applications of these nanoparticles in CRC treatment including drug delivery, thermal therapy, and nucleic acid-based gene therapy are summarized with examples provided. The last section provides a glimpse into the advantages, current limitations, and prospects of LNPs in the treatment of CRC.

Therapeutic Potential of Nanomaterial-based Drug Delivery

The medical market for sophisticated therapeutic medicine delivery systems is growing at a breakneck pace. There are many benefits to using nanotechnology and nanomaterials in treating chronic human illnesses, such as the ability to target the delivery of drugs to particular areas. Improving the therapeutic effectiveness of current and future medications might be as simple as creating new drug delivery methods. The prime applications related to nanomaterial drug delivery include immunotherapeutic agents, diagnostic testing, cancer therapy and nutraceutical delivery. Nanotechnology has the capacity to collaborate with physics, biologists, chemists and pharmaceutics to form a multidisciplinary contribution in the rise of novel diagnostic and therapeutic technology. Nanomaterials can be used in specific sites targeted by drugs for brain illnesses. These nanodrugs can cause lesser immune response and maintain low inflammatory conditions compared to heavy drug particles. Along with this, nanodrugs can cause damage at the genetic level, create oxidative stress and inhibit cell death according to their particle size, shape, surface and its composition. In this current review various applications, current trends and recent developments in nanomaterials are elucidated. The detailed mechanism and cutting edge nanomaterial based drug delivery were explained along with this.

Utilizing Macrophages Missile for Sulfate-Based Nanomedicine Delivery in Lung Cancer Therapy.

Nanomaterial-based drug delivery systems are susceptible to premature drug leakage and systemic toxicity due to lack of specific targeting, and live-cell drug delivery is also prone to be restricted by drug carrier-cell interactions. Here, a method is established to adsorb drug-loaded nanomaterials externally to the live cells, which reduces cytotoxicity caused by drug uptake and improves the bioactivity of the carrier cells and drug release at the lesion site. It was found that polyphenols act like "double-sided tape" to bridge metal-organic framework (MOF) nanoparticles with live macrophages (Mφ), attaching MOFs to the Mφ surface and minimizing intracellular uptake, with no negative effect on cell proliferation. On this basis, a "macrophage missile" with peroxymonosulfate (PMS)-loaded MOF nanoparticles on the cell surface was constructed. As a "propellant", the Mφ, in which bioactivity is preserved, can selectively identify and target tumor cells, precisely bringing nanomedicines to the lesion. MOF nanoparticles are used to load and catalyze PMS, which acts as an exogenous source of reactive oxygen species, showing higher efficacy and lower toxicity in an oxygen-independent manner. The primary study results demonstrate that this innovative combination of biology and nanomaterials remarkably enhances tumor targeting and therapeutic efficacy while reducing systemic side effects. This approach is expected to provide a more effective and safer treatment for lung cancer and holds promise for broader applications in other cancer therapies.

Nanomaterial marvels: Pioneering applications and cutting-edge advancements in drug delivery

Nanotechnology has revolutionized the field of medicine, particularly in the development of novel drug delivery systems. Nanomaterial-based drug delivery systems offer several advantages over traditional methods, including enhanced therapeutic efficacy, improved bioavailability, targeted delivery, and reduced side effects. This review provides an overview of the applications and recent advancements in nanomaterial-based drug delivery systems. The first section of this review focuses on the different types of nanomaterials used in drug delivery, including liposomes, polymeric nanoparticles, dendrimers, carbon-based nanomaterials, and metallic nanoparticles. Each nanomaterial has unique physicochemical properties that can be tailored to optimize drug encapsulation, release, and targeting. The second section highlights the importance of nanoscale characterization techniques in evaluating the properties and performance of nanomaterial-based drug delivery systems. Characterization techniques such as dynamic light scattering, transmission electron microscopy, atomic force microscopy, and spectroscopic methods enable researchers to analyze particle size, morphology, surface charge, drug loading, and release kinetics. The third section discusses the application of nanomaterial-based drug delivery systems in various therapeutic areas, including cancer treatment, cardiovascular diseases, infectious diseases, and neurological disorders. These systems can be engineered to selectively accumulate at the target site, enhancing drug efficacy and minimizing off-target effects. The fourth section explores recent advancements in nanomaterial-based drug delivery systems, including stimulus-responsive and multifunctional nanocarriers. Stimuli-responsive systems can release drugs in response to specific triggers, such as changes in pH, temperature, or enzymatic activity, leading to site-specific drug release. Multifunctional nanocarriers combine drug delivery with diagnostic imaging, allowing real-time monitoring of drug distribution and therapeutic response. The final section addresses the challenges and future perspectives in the field of nanomaterial-based drug delivery systems. Challenges include regulatory considerations, toxicity concerns, scalability, and clinical translation. Future directions involve the development of personalized nanomedicine, combination therapy approaches, and integration with other emerging technologies, such as artificial intelligence and gene editing. In conclusion, nanomaterial-based drug delivery systems have shown great potential for improving the efficacy and safety of therapeutic interventions. The advancements in nanotechnology offer exciting opportunities for the development of next-generation drug delivery platforms, opening new avenues for personalized medicine and targeted therapies. However, further research and collaborations are required to address the challenges associated with clinical translation and ensure the safe and effective implementation of these systems in clinical practice.

Role of Nanomedicine for Targeted Drug Delivery in Livestock: Future Prospective.

Nanotechnology has advanced significantly in recent years and is currently used in a wide range of sectors. Only a handful of the many diverse issues covered by nanotechnology include nanoscale gadgets, nanomaterials, nanoparticles, and nanomedicines. Its performance in treating a range of grave conditions, such as cancer, early detection of infections, analysis, bio-imaging, and bio sensing, suggests that it is highly advanced. Nanoscale materials have been employed for medicine delivery, pharmaceutics, and a range of diagnostic techniques due to their various biochemical and physical features. The use of nanoparticles that are based on nanotechnology can significantly improve the drug delivery mechanism. It is believed that nanoparticles capacity to improve the stability and solubility of drugs and shield them from impulsive inactivation during drug transfer makes it possible for them to capture, encapsulate, or bond with the molecules. The use of nanomedicine or nanoparticle-based tactics to combat viruses has emerged as a potentially life-saving tactic. These approaches have the power to protect both humans and animals against viruses. In order to inactivate a virus, nanoparticles have the unique capacity to connect with the virus epitope. Many nanocarriers have the potential to replace current drug delivery methods with focused drug delivery. Small dosages, low toxicity, and targeted flow of drug release at the infected location are all characteristics of nanocarriers or nanomedicine. Due to their distinct physicochemical and biological features, nanomaterial-based drug delivery systems (NBDDS) are frequently employed to enhance the safety and therapeutic efficacy of encapsulated pharmaceuticals. The program's objective can be supported by the applications that have so far been developed. This idea is therefore essential and sophisticated for the development of civilization. Our research will therefore concentrate on how human use of nanomedicines has changed through time in many domains.

Nanomaterial-Based Drug Delivery Systems for Ischemic Stroke.

Ischemic stroke is a leading cause of death and disability in the world. At present, reperfusion therapy and neuroprotective therapy, as guidelines for identifying effective and adjuvant treatment methods, are limited by treatment time windows, drug bioavailability, and side effects. Nanomaterial-based drug delivery systems have the characteristics of extending half-life, increasing bioavailability, targeting drug delivery, controllable drug release, and low toxicity, thus being used in the treatment of ischemic stroke to increase the therapeutic effects of drugs. Therefore, this review provides a comprehensive overview of nanomaterial-based drug delivery systems from nanocarriers, targeting ligands and stimulus factors of drug release, aiming to find the best combination of nanomaterial-based drug delivery systems for ischemic stroke. Finally, future research areas on nanomaterial-based drug delivery systems in ischemic stroke and the implications of the current knowledge for the development of novel treatment for ischemic stroke were identified.

Recent advances in nanomaterial-based drug delivery systems for melanoma therapy.

Safe and effective drug delivery is crucial for the treatment of cancer, which is quite impossible to achieve through traditional methods. Among all types of cancer, skin melanoma is known for its aggressive metastasizing ability and an unprecedented higher degree of lethalness, limiting the overall therapeutic efficacy. Here, we focus on the different types of nanomaterials (NMs) and their drug delivery applications against melanoma. All relevant publications, including research papers, reviews, chapters and patents, were assessed using search engines such as Scopus and PubMed, up to the end of August of 2023. The keywords used in the search were: nanomaterials, melanoma, drug delivery routes for melanoma, and nanomaterial-based drug delivery systems (DDS). Most of the publications out of 234 cited in this review are from the last five years. The recent advancement and mechanism of action of various NMs against melanoma, including inorganic metallic and carbon-based NMs, organic polymeric and lipid-based NMs, and cell-derived vesicles are discussed. We also focus on the application of different NMs in the delivery of therapeutic agents for melanoma therapy. In addition, the skin and melanoma, genetic mutation and pathways for melanoma, conventional treatment options, and delivery routes for therapeutic agents are also discussed briefly. There are few NM-based DDS developed in the lab set up recently. The findings of this review will pave the path for the development of NM-based DDS on an industrial scale and help in the better management of skin melanoma.

Construction of multifunctional targeted nano-prodrugs based on PAMAM dendrimers for tumor therapy

Nanomaterial-based drug delivery systems have demonstrated powerful applications in tumor therapy. PAMAM dendrimers by virtue of multivalent modification and biocompatible components were widely used to construction multifunctional targeted chemotherapeutics. In this report, we present a PAMAM dendrimer-based nano-prodrug delivery system for targeted tumor therapy. The RGDyC-PEG-PAMAM-PBA-Res (RPPPR) nano-prodrug was characterized by 1H NMR, zetasizer, and TEM, the drug loading and pH-sensitive drug release behaviors were investigated. In vitro cell viability assay revealed that the group treated with the nano-prodrug exhibited lower cell viability compared to the control group as concentration increased, confirming the nano-prodrug’s effectiveness in treating tumors. In vitro studies on cellular uptake of the nano-prodrug demonstrated that RPPPR had a high targeting ability, primarily attributed to the RGD-mediated target effect. Relevant data from our hemolysis assay indicated that the nano-prodrug maintained good blood compatibility within the concentration range of 0.1 to 0.3 mg/mL. In vivo experiments focusing on tumor therapy showed that RPPPR suppressed tumor growth and promoted tumor apoptosis. H&E staining, TUNEL assay, and immunohistochemistry results further validated the enhanced therapeutic effect. Importantly, no toxicity was observed in the vital organs such as the heart, liver, lung, kidneys, or spleen. These results suggest the superior antitumor efficacy of RPPPR compared to Resveratrol alone, and thus may be useful for tumor therapy. It is expected to explore new directions to establish a general strategy with dendritic prodrugs for synergistic tumor targeting therapy.

Nanomaterial-Based Drug Delivery Systems for Pain Treatment and Relief: From the Delivery of a Single Drug to Co-Delivery of Multiple Therapeutics.

The use of nanomaterials in drug delivery systems for pain treatment is becoming increasingly common. This review aims to summarize how nanomaterial-based drug delivery systems can be used to effectively treat and relieve pain, whether via the delivery of a single drug or a combination of multiple therapeutics. By utilizing nanoformulations, the solubility of analgesics can be increased. Meanwhile, controlled drug release and targeted delivery can be realized. These not only improve the pharmacokinetics and biodistribution of analgesics but also lead to improved pain relief effects with fewer side effects. Additionally, combination therapy is frequently applied to anesthesia and analgesia. The co-encapsulation of multiple therapeutics into a single nanoformulation for drug co-delivery has garnered significant interest. Numerous approaches using nanoformulation-based combination therapy have been developed and evaluated for pain management. These methods offer prolonged analgesic effects and reduced administration frequency by harnessing the synergy and co-action of multiple targets. However, it is important to note that these nanomaterial-based pain treatment methods are still in the exploratory stage and require further research to be effectively translated into clinical practice.

Biosynthesis and Characterization of Silver Nanoparticles Coated with Metabolites Extracted from Clerodendron phlomoides with Its Biochemical Studies in Liver Tissue

Silver nanoparticles (AgNPs) have been used as a potential nanomaterial-based drug delivery vehicle for liver cancer treatment, as it induces cell death and produces cytotoxicity against cancerous cells at a low concentration. The biosynthesis of green metallic nanoparticles uses secondary metabolites in plant extracts instead of toxic chemicals for a reduction-oxidation (redox) reaction. The biosynthesis of AgNPs with the aqueous extract of Clerodendron phlomoides was performed in this study. The phytochemical analysis of C. phlomoides extract using gas chromatography-mass spectrometry (GC-MS) confirmed the presence of redox metabolites. The peak at 489 nm in UV-visible spectra confirmed the formation of bioactive AgNPs reduced from silver nitrate solution, whereas the Fourier-transform infrared (FTIR) spectra indicated the bioactive molecules of plant extracts that are responsible for the formation. Scanning electron microscope (SEM) micrograph revealed the formation of spherical and ovoid structures of AgNPs, whereas transmission electron microscope (TEM) micrograph confirmed the size of AgNPs, which varies from 25 nm to 100 nm. X-ray diffraction (XRD) spectra showed the crystalline nature of AgNPs, and the size of crystallite was 4 nm, while dynamic light scattering (DLS) analysis confirmed the average particle size of AgNPs to be around 125 nm. In vivo studies showed that bioactive AgNPs have a significant anticancer potential against liver cancer, whereas biochemical studies of rats’ liver tissue samples confirmed that bioactive AgNPs produced a potential hepatoprotective effect against diethylnitrosamine-induced liver cancer.

Potential Role of Carbon Nanomaterials in the Treatment of Malignant Brain Gliomas.

Malignant gliomas are the most common primary brain tumors in adults up to an extent of 78% of all primary malignant brain tumors. However, total surgical resection is almost unachievable due to the considerable infiltrative ability of glial cells. The efficacy of current multimodal therapeutic strategies is, furthermore, limited by the lack of specific therapies against malignant cells, and, therefore, the prognosis of these in patients is still very unfavorable. The limitations of conventional therapies, which may result from inefficient delivery of the therapeutic or contrast agent to brain tumors, are major reasons for this unsolved clinical problem. The major problem in brain drug delivery is the presence of the blood-brain barrier, which limits the delivery of many chemotherapeutic agents. Nanoparticles, thanks to their chemical configuration, are able to go through the blood-brain barrier carrying drugs or genes targeted against gliomas. Carbon nanomaterials show distinct properties including electronic properties, a penetrating capability on the cell membrane, high drug-loading and pH-dependent therapeutic unloading capacities, thermal properties, a large surface area, and easy modification with molecules, which render them as suitable candidates for deliver drugs. In this review, we will focus on the potential effectiveness of the use of carbon nanomaterials in the treatment of malignant gliomas and discuss the current progress of in vitro and in vivo researches of carbon nanomaterials-based drug delivery to brain.

Advances in nanomaterial-based targeted drug delivery systems.

Nanomaterial-based drug delivery systems (NBDDS) are widely used to improve the safety and therapeutic efficacy of encapsulated drugs due to their unique physicochemical and biological properties. By combining therapeutic drugs with nanoparticles using rational targeting pathways, nano-targeted delivery systems were created to overcome the main drawbacks of conventional drug treatment, including insufficient stability and solubility, lack of transmembrane transport, short circulation time, and undesirable toxic effects. Herein, we reviewed the recent developments in different targeting design strategies and therapeutic approaches employing various nanomaterial-based systems. We also discussed the challenges and perspectives of smart systems in precisely targeting different intravascular and extravascular diseases.

Regenerative marine waste towards CaCO3 nanoformulation for Alzheimer's therapy

Alzheimer's disorder (AD) is associated with behavioural and cognitive destruction with due respect to the neurological degeneration. Conventional therapeutic approach for treatment of AD using neuroprotective drugs suffered certain limitations such as poor solubility, insufficient bioavailability, adverse side effects at higher dose and ineffective permeability on blood brain barrier (BBB). Development of nanomaterial based drug delivery system helped to overcome these barriers. Hence the present work focused on encapsulating neuroprotective drug citronellyl acetate within CaCO3 nanoparticles to develop neuroprotective CaCO3 nanoformulation (CA@CaCO3 NFs). CaCO3 was derived from marine conch shell waste, while the neuroprotective drug citronellyl acetate was scrutinized by in-silico high throughput screening. In-vitro findings revealed that CA@CaCO3 nanoformulation exhibited enhanced free radical scavenging activity of 92% (IC50 value - 29.27 ± 2.6 μg/ml), AChE inhibition of 95% (IC50 value - 25.6292 ± 1.5 μg/ml) at its maximum dose (100 μg/ml). CA@CaCO3 NFs attenuated the aggregation of β-amyloid peptide (Aβ) and also disaggregated the preformed mature plaques the major risk factor for AD. Overall, the present study reveals that CaCO3 nanoformulations exhibits potent neuroprotective potential when compared to the CaCO3 nanoparticles alone and citronellyl acetate alone due to the sustained drug release and synergistic effect of CaCO3 nanoparticles and citronellyl acetate depicting the fact that CaCO3 can act as promising drug delivery system for treatment of neurodegenerative and CNS related disorders.

Stimuli-Responsive Boron-Based Materials in Drug Delivery.

Drug delivery systems, which use components at the nanoscale level as diagnostic tools or to release therapeutic drugs to particular target areas in a regulated manner, are a fast-evolving field of science. The active pharmaceutical substance can be released via the drug delivery system to produce the desired therapeutic effect. The poor bioavailability and irregular plasma drug levels of conventional drug delivery systems (tablets, capsules, syrups, etc.) prevent them from achieving sustained delivery. The entire therapy process may be ineffective without a reliable delivery system. To achieve optimal safety and effectiveness, the drug must also be administered at a precision-controlled rate and the targeted spot. The issues with traditional drug delivery are overcome by the development of stimuli-responsive controlled drug release. Over the past decades, regulated drug delivery has evolved considerably, progressing from large- and nanoscale to smart-controlled drug delivery for several diseases. The current review provides an updated overview of recent developments in the field of stimuli-responsive boron-based materials in drug delivery for various diseases. Boron-containing compounds such as boron nitride, boronic acid, and boron dipyrromethene have been developed as a moving field of research in drug delivery. Due to their ability to achieve precise control over drug release through the response to particular stimuli (pH, light, glutathione, glucose or temperature), stimuli-responsive nanoscale drug delivery systems are attracting a lot of attention. The potential of developing their capabilities to a wide range of nanoscale systems, such as nanoparticles, nanosheets/nanospheres, nanotubes, nanocarriers, microneedles, nanocapsules, hydrogel, nanoassembly, etc., is also addressed and examined. This review also provides overall design principles to include stimuli-responsive boron nanomaterial-based drug delivery systems, which might inspire new concepts and applications.

Fabrication of novel ruthenium loaded silk fibroin nanomaterials for fingolimod release improved antitumor efficacy in hepatocellular carcinoma

Cancer targeted nanomaterials-based drug delivery systems have been described as promising. In this work, we employed silk fibroin (SF), ruthenium nanomaterials (RuNMs), heptapeptide (T7), and fingolimod (FTY720) to construct a pH-responsive smart nanomaterials drug delivery system. They were spherical with a mean size of around 120 nm, which may have contributed to the improved penetration and retention of the NMs in tumour areas. T7-FTY720@SF-RuNMs had an encapsulation efficiency (EE) of 72.51 ± 4.02%. When the pH of an environment is acidic, the release of FTY720 from nanocarriers is enhanced. T7-FTY720@SF-RuNMs demonstrated increased cellular uptake selective and anticancer efficacy for hepatocellular cancer in both in vitro and in vivo experiments. Additionally, the in vivo biodistribution investigation showed that T7-FTY720@SF-RuNMs could efficiently aggregate in the tumour location, improving their in vivo potential to kill cancer cells. T7-FTY720@SF-RuNMs demonstrated little toxicity to tumour-bearing animals in investigations of histology and immunohistochemistry, showing that the fabricated NMs are biocompatible in vivo. For the treatment of hepatocellular cancer, the T7-FTY720@SF-RuNMs delivery method offers significant promise.

Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy.

Cancer immunotherapy, a major breakthrough in cancer treatment, has been successfully applied to treat a number of tumors. However, given the presence of factors in the tumor microenvironment (TME) that impede immunotherapy, only a small proportion of patients achieve a good clinical response. With the ability to increase permeability and cross biological barriers, nanomaterials have been successfully applied to deliver immunotherapeutic agents, thus realizing the anti-cancer therapeutic potential of therapeutic agents. This has driven a wave of research into systems for the delivery of immunotherapeutic agents, which has resulted in widespread interest in nanomaterial-based drug delivery systems. Nanomaterial-based drug delivery systems are able to overcome the challenges from TME and thus achieve good results in cancer immunotherapy. If it can make a breakthrough in improving biocompatibility and reducing cytotoxicity, it will be more widely used in clinical practice. Different types of nanomaterials may also have some subtle differences in enhancing cancer immunotherapy. Moreover, delivery systems made of nanomaterials loaded with drugs, such as cytotoxic drugs, cytokines, and adjuvants, could be used for cancer immunotherapy because they avoid the toxicity and side effects associated with these drugs, thereby enabling their reuse. Therefore, further insights into nanomaterial-based drug delivery systems will provide more effective treatment options for cancer patients.

Hyaluronic Acid-Based Nanomaterials Applied to Cancer: Where Are We Now?

Cancer cells normally develop the ability to rewire or reprogram themselves to become resistant to treatments that were previously effective. Despite progress in understanding drug resistance, knowledge gaps remain regarding the underlying biological causes of drug resistance and the design of cancer treatments to overcome it. So, resistance acquisition remains a major problem in cancer treatment. Targeted therapeutics are considered the next generation of cancer therapy because they overcome many limitations of traditional treatments. Numerous tumor cells overexpress several receptors that have a high binding affinity for hyaluronic acid (HA), while they are poorly expressed in normal body cells. HA and its derivatives have the advantage of being biocompatible and biodegradable and may be conjugated with a variety of drugs and drug carriers for developing various formulations as anticancer therapies such as micelles, nanogels, and inorganic nanoparticles. Due to their stability in blood circulation and predictable delivery patterns, enhanced tumor-selective drug accumulation, and decreased toxicity to normal tissues, tumor-targeting nanomaterial-based drug delivery systems have been shown to represent an efficacious approach for the treatment of cancer. In this review, we aim to provide an overview of some in vitro and in vivo studies related to the potential of HA as a ligand to develop targeted nanovehicles for future biomedical applications in cancer treatment.

Glutaraldehyde crosslinked doxorubicin promotes drug delivery efficiency using cobalt ferrite nanoparticles

Doxorubicin (DOX) is a common chemotherapy agent that is used in clinics for the treatment of a wide spectrum of cancers. Herein, a novel approach for improving doxorubicin loading on nanoparticles and also controlled release is suggested using crosslinking doxorubicin molecules with glutaraldehyde. We investigated the loading efficiency of doxorubicin on CoFe2O4 nanoparticles in the absence and presence of glutaraldehyde. Based on the feasible, one-pot, and time-saving approach suggested here, the crosslinked DOX showed loading efficiency about twice more in comparison with the non-crosslinked DOX. In vitro doxorubicin release of three formulations including DOX crosslinked with glutaraldehyde (DOXGA), DOX loaded on CoFe2O4 (CFDOX) and DOX loaded on CoFe2O4 using glutaraldehyde (CFDOXGA) yielded a sustained release. The kinetic models such as first-order, Sahlin-Peppas, and Higuchi were employed for further exploration of DOX release profile. Our suggested method might extend to other nanomaterial-based drug delivery formulations to promote drug delivery efficiency.